
Glaukos shares jump nearly 10% after strong Q2 earnings and raised 2026 sales forecast.
Glaukos reported a better-than-expected Q2 2026 with an adjusted loss of $0.14 per share, beating estimates, and revenues up 50% to $185.6 million, driven by strong sales of its iDose TR product. The company raised its 2026 sales guidance to $680-$70...



